Here the authors identify arylsulfatase A as a NASH-induced hepatokine that inhibits hepatic lysophosphatidylcholine and lysophosphatidic acid secretion, and improves muscle insulin action and systemic glucose homeostasis. This evidence concerns the gene ARSA and metabolic dysfunction-associated steatohepatitis.